Home/Arovella/Dr Michael Baker
DM

Dr Michael Baker

CEO & Managing Director

Arovella

Therapeutic Areas

Arovella Pipeline

DrugIndicationPhase
ALA-101CD19+ B‑cell lymphomas and leukaemiasPreclinical
ALA-105Claudin‑18.2+ gastric, gastro‑oesophageal junction, and pancreatic cancersPreclinical